GC
VRTX icon

Grimes & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Grimes & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
759
+111
+17% +$49.2K 0.01% 347
2026
Q1 		$289K Buy
648
+12
+2% +$5.6K 0.01% 365
2025
Q4 		$288K Buy
636
+15
+2% +$6.46K 0.01% 388
2025
Q3 		$243K Sell
621
-87
-12% -$36.4K 0.01% 404
2025
Q2 		$315K Buy
708
+2
+0.3% +$922 0.01% 330
2025
Q1 		$342K Buy
706
+57
+9% +$26.6K 0.01% 279
2024
Q4 		$261K Buy
649
+19
+3% +$8.81K 0.01% 328
2024
Q3 		$293K Buy
630
+1
+0.2% +$480 0.01% 293
2024
Q2 		$295K Buy
629
+22
+4% +$9.55K 0.01% 273
2024
Q1 		$254K Buy
607
+98
+19% +$41.4K 0.01% 290
2023
Q4 		$207K Buy
+509
New +$188K 0.01% 301
2022
Q2 		– Sell
-911
Closed -$238K – 301
2022
Q1 		$238K Buy
+911
New +$216K 0.01% 265

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Grimes & Company's VRTX Position: Q2 2026 in Review

Grimes & Company increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, buying an estimated $49.2K and bringing the position to 759 shares worth $377K. The position accounts for 0.01% of the portfolio, ranked #347.

Grimes & Company first reported a position in VRTX in Q1 2022 and has held it in 12 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Grimes & Company held 759 shares of Vertex Pharmaceuticals worth $377K as of Q2 2026.
  • Grimes & Company bought 111 Vertex Pharmaceuticals shares in Q2 2026, an estimated $49.2K.
  • Vertex Pharmaceuticals made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #347 holding.
  • Grimes & Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.